Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTsp Advanced Technologies Plc Regulatory News (TSP.PL)

Share Price Information for Tsp Advanced Technologies Plc (TSP.PL)

Share Price is delayed by 15 minutes
Get Live Data
0.45    0.00 (0.00%)
Bid:
0.35
Ask:
0.55
Spread: 0.20 (57.143%)
Market Cap: £842.85k
TSP.PL Live PriceLast checked at - Aquis Stock Exchange

Intraday Tsp Advanced Technologies Plc Share Chart

Proposed Director Appointments & Update

18 Sep 2023 07:00

RNS Number : 6547M
TruSpine Technologies PLC
18 September 2023
 

18 September 2023

 

TruSpine Technologies plc

("TruSpine" or the "Company")

 

Proposed Director Appointments & Update

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering "screwless," spinal (vertebral) stabilisation systems announces the proposed appointments of Victoria Sena and Samuel Ogunsalu as Non-Executive Directors of the Company, subject to standard regulatory due diligence.

Proposed Director Appointments

Victoria Sena founded Cherrybank Consulting Limited in 2019 to assist clients in the areas of governance, operations, risk, and compliance. Previously Victoria spent eight years at the Bank of England in the authorisations, banking, and insurance divisions, and completed a secondment to the Treasury Committee of the House of Commons. After moving to the private sector Victoria served as a Group Risk Manager for an international insurance group, before becoming Chief Operating Officer of a boutique investment manager where she was an FCA Approved Person. She is a Chartered Member of the Chartered Institute of Securities and Investments and holds degrees from Oxford University and the London School of Economics and Political Science.

Samuel Ogunsalu has over 20 years' experience in technology commercialisation, licensing, and business development. He has executed a wide number of transactions ranging from negotiating licences and M&As, to transformational technology partnerships with companies such as Merck, GSK, Pharmacia (merged with Pfizer) and Abbott (now AbbVie) as well as helping to establish preclinical research programmes with a number of industrial partners and set up joint ventures, start-ups, and spinout companies to develop novel technologies. Samuel was previously Chief Business Officer & Director of an oncology company and Chief Commercial Officer of an AIM listed biotech company. Prior to that he has held a number of positions across technology business units connected with Queen Mary College, London, as well as other roles in which he has advised private and listed companies in both the UK and the USA. He started his professional career as a pilot plant engineer at Imperial College, London, followed by scientific research at University College London, before moving into business & commercial development. Samuel holds a BSc in Microbiology from the University of Wales, and an MSc in Biochemical Engineering from UCL.

A further announcement will be made in due course following completion of standard regulatory due diligence.

Update

Further to the announcement of 17 August 2023, the Company announces that it will not appeal the Disciplinary Notice published by the Aquis Stock Exchange which resulted from the Aquis Disciplinary Investigation. The Company accepts the findings of the Aquis Disciplinary Investigation.

The Company believes that the appointments of Victoria Sena and Samuel Ogunsalu will improve the corporate governance at the Company.

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 17 August 2023.

The Directors of the Company are responsible for the release of this announcement.

Enquiries:

TruSpine Technologies Plc

Tel: +44 (0)20 7118 0852

Laurence Strauss, Chief Executive Officer

Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti

Peterhouse Capital Limited (Broker & Financial Adviser)

 Tel: +44 (0)20 7469 0930

Lucy Williams / Duncan Vasey

 

Novus Communications (PR and IR)

Tel: +44 (0)20 7448 9839

Alan Green / Jacqueline Briscoe

novuscomms@truspine.org

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identied by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXGPUPWBUPWGWA
12
Date   Source Headline
30th Dec 20257:00 amRNSHalf-year Report
30th Dec 20257:00 amRNSHalf-year Report
10th Dec 202511:36 amRNSResult of 2025 AGM
17th Nov 202512:45 pmRNSNotice of AGM
5th Nov 20254:00 pmRNSChange of Name
16th Oct 20257:00 amRNSHolding(s) in Company
15th Oct 202510:30 amRNSSubscription, Director/PDMR Dealing & RPT
14th Oct 20255:00 pmRNSFinal Results
1st Oct 20257:00 amRNSDelay to the publication of accounts & Suspension
22nd Aug 202511:34 amRNSResult of GM
15th Aug 20252:37 pmRNSIssue of Warrant
4th Aug 202510:45 amRNSNotice of GM
3rd Jul 20257:00 amRNSBitcoin Treasury Policy Update
1st Jul 20257:00 amRNSConvertible Loan Note Extension & RPT
25th Jun 20257:00 amRNSBitcoin Treasury Policy
29th May 20257:00 amRNSHolding(s) in Company
23rd May 20257:00 amRNSSubscription, RPT, Issue of Equity
20th May 20257:00 amRNSUpdate on AQSE Fine
25th Apr 202511:32 amRNSIssue of Equity
10th Apr 202512:42 pmRNSResult of 2024 AGM & Directorate Change
10th Apr 20257:00 amRNSAGM Statement
7th Apr 20257:00 amRNS-RWebinar
17th Mar 20254:00 pmRNSNotice of 2024 AGM
24th Dec 20247:00 amRNSHalf-year Report
30th Sep 20247:00 amRNSFinal Results
24th Jul 20247:00 amRNSConvertible Loan Note Extension & RPT
19th Jun 20247:54 amRNSHolding(s) in Company
17th Jun 20245:30 pmRNSShare Transfer, Director/PDMR dealing and RPT
14th Jun 20248:50 amRNSHolding(s) in Company
13th Jun 202411:29 amRNSHolding(s) in Company
7th Jun 20242:24 pmRNSResult of 2023 AGM
7th Jun 20247:15 amRNSNew Interactive Investor Hub
7th Jun 20247:00 amRNSAGM Statement & Change of Website
5th Jun 20248:06 amRNSConvertible Loan Note Conversion & Issue of Equity
29th May 20249:29 amRNSHolding(s) in Company
29th May 20247:40 amRNSHolding(s) in Company
28th May 20247:45 amRNSShare Transfer, Director/PDMR dealing and RPT
10th May 20247:02 amRNSNotice of 2023 AGM
7th May 20247:00 amRNSDirectorate Change
28th Mar 20247:00 amRNSConvertible Loan Note, Debenture and AGM Update
25th Mar 20247:00 amRNSHolding(s) in Company
21st Mar 20247:00 amRNSDirector/PDMR Shareholding
20th Mar 20242:28 pmRNSHolding(s) in Company
20th Mar 202412:22 pmRNSHolding(s) in Company
18th Mar 20247:00 amRNSDirector/PDMR Shareholding
15th Mar 20242:49 pmRNSResult of Adjourned AGM
15th Mar 202410:00 amRNSAGM Statement & Loans Update
14th Mar 20247:00 amRNSIssue of Equity, Warrant Surrender, CLN & RPT
28th Feb 202412:30 pmRNSDirector Appointments
22nd Feb 202410:42 amRNSShareholder Requisition Notice
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.